Origin of Connective Tissue Type Mesotheliomas from Multipotential Spindle Cells

Origin of Connective Tissue Type Mesotheliomas from Multipotential Spindle Cells


Free Online Articles Directory





Why Submit Articles?
Top Authors
Top Articles
FAQ
AB Answers

Publish Article

0 && $.browser.msie ) {
var ie_version = parseInt($.browser.version);
if(ie_version Hello Guest
Login


Login via


Register
Hello
My Home
Sign Out

Email

Password


Remember me?
Lost Password?

Home Page > Health > Cancer > Origin of Connective Tissue Type Mesotheliomas from Multipotential Spindle Cells

Origin of Connective Tissue Type Mesotheliomas from Multipotential Spindle Cells

Edit Article |

Posted: Oct 24, 2010 |Comments: 0

|

Share

]]>

Syndicate this Article

Copy to clipboard

Origin of Connective Tissue Type Mesotheliomas from Multipotential Spindle Cells

By: Montwrobleski77

About the Author

Monty Wrobleski is the author of this article.  For more information please click on the following links

Depuy Hip Recall Attorney

Depuy ASR Recall

Depuy Hip Recall

(ArticlesBase SC #3536196)

Article Source: http://www.articlesbase.com/Origin of Connective Tissue Type Mesotheliomas from Multipotential Spindle Cells

Another interesting study is called, “Pleural mesothelioma of connective tissue type, localized fibrous tumour of the pleura, and reactive submesothelial hyperplasia. An immunohistochemical comparison” by Moutaiz Al-Izzi, Nicola P. Thurlow, Professor Bryan Corrin – The Journal of Pathology Volume 158, Issue 1, pages 41–44, May 1989.  Here is an excerpt: “Abstract – Ten diffuse pleural mesotheliomas of connective tissue type have been compared with 14 examples of pleural granulation tissue and 7 localized fibrous tumours of the pleura, using immunohistochemistry to identify cytokeralins oflow and high molecular weight and vimentin. Low molecular weight cytokeratin and vimentin were both delected in 8 of the 10 mesotheliomas and in 12 of the 14 reactive iesions. High molecular weight cylokeratin was rarely detected in either lesion. The seven localized fibrous tumours of the pleura were all positive for virnentin and negative for both cytokeratins. These findings support an origin of connective tissue type mesotheliomas from multipotential submesothelial spindle cells and of localized fibrous tumours of the pleura from either conventional fibroblasts or resting submesothelial spindle cells. Antibodies to cytokeratin help distinguish these two neoplasms but provide no assistance in the more difficult diagnostic problem of distinguishing mesotheliomas of connective tissue type from pleural reactions characterized by abundant granulation tissue.”

Another interesting study is called, “Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM)” –
Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting edition). Vol 25, No 18S (June 20 Supplement), 2007: 7526 by T. Karrison, H. L. Kindler, D. R. Gandara, C. Lu, T. L. Guterz, K. Nichols, H. Chen, W. M. Stadler and E. E. Vokes – University of Chicago Medical Center, Chicago, IL; UC Davis Cancer Center, Sacramento, CA; MD Anderson Cancer Center, Houston, TX; CTEP National Cancer Institute, Rockville, MD.  Here is an excerpt: “Background: In phase II trials in MM, GC on a 21-day (D) schedule has response rates of 16%–26% and median overall survival (OS) of 9.6–13 months (mo). Since VEGF has a key role in MM biology, we added anti-VEGF antibody B to GC in a multi-center, double- blind, placebo-controlled randomized phase II trial. Methods: Eligible pts had unresectable MM; no prior chemotherapy; PS 0–1; no thrombosis, bleeding, or major vessel invasion. Primary endpoint: progression-free survival (PFS). Statistics: 90% power to detect HR 0.57. Stratification: PS (0/1), histology (epithelial/other). G 1,250 mg/m2 D 1, 8 Q21D, C 75 mg/m2 D1 Q21D, and B 15 mg/kg or P D1 Q21D was given x 6 cycles, then B or P Q21D until progression. Baseline plasma VEGF was measured. 115 pts enrolled 12/01- 07/05 at 11 sites, 108 (GCB/GCP) 53/55 were evaluable. Male 74%/84%; median age 62/65 (range 44–78/20–84); PS 1 55%/47%; epithelial 74%/67%; pleural 93%/91%; thrombocytosis 40%/40%. Results: Cycles: total 458/424, median 7/6, range 1–42/2–39. Statistically significantly different (SSD) toxicity (p <0.05), any grade: alopecia 60%/38%; epistaxis 62%/24%; hypertension 45%/22%; non-neutropenic infection 15%/4%; proteinuria 62%/47%; stomatitis 23%/7%. There were no SSD toxicities = grade 3. Median PFS 6.9/6.0 mo (HR 0.93, p=0.88). Median OS 15.6/14.7 mo (p=0.91). 1-year survival 59%/57%. Partial response 25%/22%; stable disease 51%/60%. Median VEGF (N=56) 131/154 pg/ml (range 31–1760/5–1786). Higher VEGF was associated with shorter PFS (p=0.02) and OS (p=0.0066). In pts with VEGF = the median, PFS (p=0.043) and OS (p=0.028) were significantly greater for GCB than GCP; in high VEGF strata this was not SSD. Conclusion: Adding B to GC in MM pts does not yield statistically significant differences in PFS, OS, response, or grade  toxicity. GCB-treated pts with low VEGF levels had longer PFS and OS. Supported by NCI grant N01-CM-17102.”

Another interesting study is called, “Technique for external beam treatment for Mesothelioma” by G.J. Kutcher, PH.D., C. Kestler, R.T., D. Greenblatt, M.D., H. Brenner, M.D., B.S. Hilaris, M.D., D. Nori, M.D. – Volume 13, Issue 11, Pages 1747-1752 (November 1987).  Here is an excerpt: “Abtract – A combined photon-electron beam treatment for diffuse pleural mesothelioma is discussed in this paper. The technique consists of parallel opposed 10 MV X rays prescribed to 4250 cGy using customized blocks to shield the lung. The pleura is then boosted with electrons to a dose of 3600 cGy. The combination yields a TDF of 74 ret to the pleura. As discussed in an earlier paper, this treatment method when combined with subtotal pleurectomy and I-125 implantation leads to improved survivals with minimal complications. The details of this 3-dimensional radiation treatment method were not described in detail. To improve target coverage and local control, the technique has been modified. CT is now used along with simulation plane films to define the entire pleural surface. The target volume has also been extended from the dome to the base of this diaphragm. These changes have led to improved pleural dose distributions; by blocking the liver or stomach, and boosting the crus of the diaphragm with electrons, there is little added morbidity. As is demonstrated by dose volume histograms, we have been able to deliver 4250 cGy 10% to most of the pleura with ; of the lung parenchyma receiving less than 2100 cGy.”

Another interesting study is called, “Laparoscopy: An important tool in the staging of malignant pleural Mesothelioma” by Kevin C. Conlon, Valerie W. Rusch and Susan Gillern – Annals of Surgical Oncology Volume 3, Number 5, 489-494, DOI: 10.1007 — Here is an excerpt: “Abstract – Background: The current standard for the noninvasive staging of patients with malignant pleural mesothelioma is computed tomography (CT). However, CT often cannot determine whether a tumor is unresectable because of direct extension through the diaphragm to the peritoneal cavity. The aim of this prospective study was to determine whether laparoscopy detected transdiaphragmatic tumor extension when CT findings were equivocal.

Methods: From June 1993 to July 1994, 12 of 36 patients considered for possible thoracotomy and surgical resection had equivocal CT findings of diaphragmatic invasion. All underwent laparoscopy using a multiport technique with diaphragmatic and peritoneal biopsies.

Results: The mean operative time was 83 min. There were no perioperative complications. The median hospital stay was 1 day. Six patients had biopsy-proven transdiaphragmatic extension, or peritoneal studding of tumor. The other six patients subsequently underwent thoracotomy: three had a complete resection, and three had unresectable tumor due to chest wall (N=2) or mediastinal (N=1) invasion. In no case was transdiaphragmatic extension of a tumor seen.

Conclusions: This preliminary experience demonstrates that laparoscopy is a safe and accurate method for detecting transdiaphragmatic tumor extension when CT fails to do so. Laparoscopy should be considered a standard part of prethoracotomy staging in this subset of patients.”

Retrieved from “http://www.articlesbase.com/cancer-articles/origin-of-connective-tissue-type-mesotheliomas-from-multipotential-spindle-cells-3536196.html

(ArticlesBase SC #3536196)

Montwrobleski77 -
About the Author:

Monty Wrobleski is the author of this article.  For more information please click on the following links

Depuy Hip Recall Attorney

Depuy ASR Recall

Depuy Hip Recall

]]>

Rate this Article

1
2
3
4
5

vote(s)
0 vote(s)

Feedback
RSS
Print
Email
Re-Publish

Source:  http://www.articlesbase.com/cancer-articles/origin-of-connective-tissue-type-mesotheliomas-from-multipotential-spindle-cells-3536196.html

Article Tags:
asbestos exposure, mesothelioma cancer, asbestos attorney, lawyer, class action lawyers, law suit, suite, law firm, law firms, litigation, treatment, lung cancer, patients, victims, meso lawyer, faq, navy veterans, symptoms, asbestos poisoning, damage, pl

Related Videos

Related Articles

Latest Cancer Articles
More from Montwrobleski77


Dr David Sanderson Explain Mesothelioma

Dr. David Sanderson describes mesothelioma and explains how asbestos contributes to lung cancer. (01:39)


The Cancerous Nature of Soft Tissue Tumors

Dr. Templeton shares if all soft tissue tumors are cancerous. (00:48)


How to Find Breast Cancer in Women with Dense Breast Tissue

Dr. Jennifer Engles Discusses Why It Is More Difficult To Find Breast Cancer In Women With Dense Breast Tissue? . (01:42)


What Soft Tissue Sarcoma is

Dr. Templeton explains soft tissue sarcoma, which is a form of sarcoma that develops in connective tissue. (01:03)


Tissue Transfer For Skin Cancer

This medical video shows how tissue transfer can help those with skin cancer. (01:17)

Upper Lobe Tumors and Asbestos Exposure

Deaths due to mesothelioma could have been avoided

By:
Montwrobleski77l

Health>
Cancerl
Aug 21, 2010

Premature Death of Workers Caused by Asbestos Exposure and Mesothelioma

Spreading the word about asbestos related disease is the first step towards finding a cure

By:
Montwrobleski77l

Health>
Cancerl
Aug 21, 2010

Parenchymal Abnormalities Asbestos Exposure and Disease Development

Asbestos disease is deadly and more common than you think

By:
Montwrobleski77l

Health>
Cancerl
Sep 05, 2010

Peritoneal Mesothelioma Patients Generally Present with Two Types of Symptoms

Aberrant activation and upregulation of the Wnt pathway is a key feature of many cancers

By:
Montwrobleski77l

Health>
Cancerl
Oct 02, 2010

Asbestos Exposure and Ferruginous Bodies in the Lungs

Asbestos has been documented as a contaminant of some older cosmetic talc preparations, the chrysotile and crocidolite types of asbestos are more indicative of background and occupational exposure

By:
Montwrobleski77l

Health>
Cancerl
Sep 19, 2010

Peripheral Tumours Mesothelioma Disease Development and Asbestos Exposure

The majority of cases with asbestos-related diseases had experienced their first asbestos exposure prior to 1960. For cases with first asbestos exposure after 1960, a shift was observed from the primary asbestos industry towards asbestos-using industries

By:
Montwrobleski77l

Health>
Cancerl
Sep 20, 2010

Mean Durations of Asbestos Exposure and Chest Abnormalities

It is believed that a program of medical awareness should be instituted in work areas where people are employed in the mining, processing and use of asbestos

By:
Montwrobleski77l

Health>
Cancerl
Sep 19, 2010

Mesothelioma Disease and Lung Cancer as it Relates to Cigarette Smoke and Asbestos Exposure

The relative risk of lung cancer from asbestos exposure is about twice as high in non-smokers as in smokers

By:
Montwrobleski77l

Health>
Cancerl
Sep 14, 2010

Symptoms of Extra Weight From an Under Active Thyroidh

Complex carbohydrates, too, should be used in an underactive thyroid diet, albeit somewhat sparingly.

By:
ShawnClerkl

Health>
Cancerl
Nov 15, 2010

Herbals for Lung Cancer

Fruits and vegetables for lung cancer and how to prevent cancer. Some tips to avoid cancer

By:
aselim84l

Health>
Cancerl
Nov 13, 2010

Indiana University Study Shows Blend Of 6 Mushrooms Fight Breast Cancer

An recent study out of Indiana University and Methodist Research Institute shows promising effects of a formula to support cellular breast health.

By:
Alberto Stellpflugl

Health>
Cancerl
Nov 13, 2010

Breast Cancer Risk – Discover the Hidden Link

Everything your body does or cannot do is affected by nutrition. If you have good nutrition, you can actually speed the process in which your body heals from surgery,

By:
Barb Lulayl

Health>
Cancerl
Nov 12, 2010

Discover Natural Ways to Stop Snoring

Try to stay away from relaxants like drugs, alcohol, cigarettes, and other medications because they are known to influence your snoring.

By:
Tom Mackl

Health>
Cancerl
Nov 11, 2010

Lung Cancer Therapies

Lung cancer is a benign tumor in the lungs. It is the leading cause of cancer related deaths among men and women.

By:
wendyl

Health>
Cancerl
Nov 11, 2010

Breast Cancer Awareness

This October is the month of the Breast Cancer Awareness. Lots of people are going to cooperates in this event through wearing pinks. It is very important that we became a part of this kind of events, to educate people around the globe about this kind of illness.

By:
kimberly valeriol

Health>
Cancerl
Nov 11, 2010

Thyroid Cancer, “A Real Cancer”

Unless you have a goiter or an obvious cyst growing on your thyroid gland, it can be hard to believe that you really have thyroid cancer when diagnosed. A lot of times there are no obvious symptoms.

By:
Elaine Savardl

Health>
Cancerl
Nov 10, 2010

Mesothelioma Therapy with the Antiestrogen Tamoxifen

Therapy with the antiestrogen tamoxifen in this setting may provide an option for long-term medical management in cases of symptomatic recurrent cystic mesotheliomas

By:
Montwrobleski77l

Health>
Cancerl
Oct 28, 2010

Mesothelioma and Histological Evidence of Extra Pleural Lymph Node Metastases

Pathological nodal involvement cannot be predicted from nodal dimensions. These data suggest that all patients being considered for radical resection of MPM should preferentially undergo preoperative cervical mediastinoscopy irrespective of radiological findings

By:
Montwrobleski77l

Health>
Cancerl
Oct 28, 2010

Do Markers Provide Higher Diagnostic Accuracy for Mesothelioma

Various antibody panels have been recommended for the diagnosis of MM, with no overall consensus about how many and which markers should be used. A recent study with Bayesian statistics has demonstrated that the use of many markers does not provide higher diagnostic accuracy than the use of selected single antibodies or various combinations of only 2 markers

By:
Montwrobleski77l

Health>
Cancerl
Oct 28, 2010

Mesothelioma and Effects of Epigenetic and Genetic Alterations

Although the association between TSP-1 and VEGF has not been well defined, the effect of VEGF should be considered when attempting to determine the impact of TSP-1 on prognosis

By:
Montwrobleski77l

Health>
Cancerl
Oct 28, 2010

Mesothelioma Cell Lines Using Indirect Immunofluorescence and Northern Blotting

Many controversial issues still exist in the treatment of malignant pleural mesothelioma. In the ensuing years newer staging systems, better preoperative staging, newer experimental therapies, and the localization of patients at expert centers will undoubtedly have an impact on disease management.

By:
Montwrobleski77l

Health>
Cancerl
Oct 27, 2010

Mesothelioma and Continuous Infusion Paclitaxel Administered with Large Field Irradiation

Together with identification of the antigen in serum, pleural fluid, or ascitic fluid, immunohistochemical and immunocytochemical techniques for detecting carcinoembryonic antigen provide a valuable aid for distinguishing malignant mesothelioma from metastatic carcinomas.

By:
Montwrobleski77l

Health>
Cancerl
Oct 27, 2010

Mesothelioma Multimodality Approach with CAP Chemotherapy

The use of extrapleural pneumonectomy in a multimodality treatment setting for malignant pleural mesothelioma is described, presenting first the right-sided approach and then the left-sided. This technique used in a multimodality approach with CAP chemotherapy.

By:
Montwrobleski77l

Health>
Cancerl
Oct 27, 2010

Mesothelioma and Murine Models of Melanoma and Adenocarcinoma

There is good evidence to recommend chemotherapy with pemetrexed and cisplatin for adult patients with symptomatic advanced malignant pleural mesothelioma. Such treatment should be administered with supplementation of vitamin B12 and folic acid

By:
Montwrobleski77l

Health>
Cancerl
Oct 27, 2010

Add new Comment

Your Name: *

Your Email:

Comment Body: *

 

Verification code:*

* Required fields

Submit

Your Articles Here
It’s Free and easy

Sign Up Today

Author Navigation

My Home
Publish Article
View/Edit Articles
View/Edit Q&A
Edit your Account
Manage Authors
Statistics Page
Personal RSS Builder

My Home
Edit your Account
Update Profile
View/Edit Q&A
Publish Article
Author Box


Montwrobleski77 has 234 articles online

Contact Author

Subscribe to RSS

Print article

Send to friend

Re-Publish article

Articles Categories
All Categories

Advertising
Arts & Entertainment
Automotive
Beauty
Business
Careers
Computers
Education
Finance
Food and Beverage
Health
Hobbies
Home and Family
Home Improvement
Internet
Judaism
Law
Marketing
News and Society
Relationships
Self Improvement
Shopping
Spirituality
Sports and Fitness
Technology
Travel
Writing

Health

Acne
Allergies
Alternative Medicine
Anti Aging
Cancer
Dental Care
Disabilities
Diseases and Conditions
Hair Loss
Hearing
Medical Tourism
Medicine
Men’s Health
Mental Health
Nutrition
Plastic Surgeries
Quit Smoking
Sleep
Supplements & Vitamins
Vision
Wellness
Women’s Health

]]>

Need Help?
Contact Us
FAQ
Submit Articles
Editorial Guidelines
Blog

Site Links
Recent Articles
Top Authors
Top Articles
Find Articles
Site Map

Webmasters
RSS Builder
RSS
Link to Us

Business Info
Advertising

Use of this web site constitutes acceptance of the Terms Of Use and Privacy Policy | User published content is licensed under a Creative Commons License.
Copyright (c) 2005-2010 Free Articles by ArticlesBase.com, All rights reserved.

Originally published here.


Monty Wrobleski is the author of this article.  For more information please click on the following links

Depuy Hip Recall Attorney

Depuy ASR Recall

Depuy Hip Recall


Leave a Reply

You must be logged in to post a comment.